

September 29, 2023

Ramsey M. Al-Salam
RAIsalam@perkinscoie.com
D. +1.206.359.6385
F. +1.206.359.7385

VIA OVERNIGHT DELIVERY

Imperative Care, Inc.
Attn: Fred Khosravi, CEO
Ronald Austin, General Counsel
1359 Dell Avenue
Campbell, CA 95008

TruVic Medical, Inc./Imperative Care
Vascular
Attn: President
1359 Dell Avenue
Campbell, CA 95008

Re: Imperative Care/TruVic's Infringement of Inari Medical's Patents

Dear Messrs. Khosravi and Austin:

We represent Inari Medical, Inc. As you know, Inari is the world's leading developer of catheter-based mechanical thrombectomy devices that treat pulmonary embolism (PE) and deep vein (DVE) thrombosis through aspiration and mechanical mechanisms of action. Inari's products, including its FlowTrier and ClotTrier systems, have received widespread acclaim for their efficacy. See www.inarimedical.com/int/in-the-news/. Inari's innovations have also been repeatedly recognized by the United States Patent and Trademark Office, which has issued Inari approximately 40 United States patents and is in the process of allowing additional claims in multiple pending applications. Inari also has multiple foreign patents and applications. For your convenience, Attachment A to this letter contains a current list of Inari's issued patents and published applications.

We understand that, in addition to its recent Prodigy system, TruVic¹ has been promoting a Symphony Thrombectomy system, has received a letter from FDA with 510k clearance for the system, and is close to launching that system. Based upon the promotional literature that TruVic has distributed, it appears that the manufacture, sale, offer for sale, and/or use of the Symphony system may infringe Inari's current patent rights and will infringe pending patents, if and when they issue. For example, even without the benefit of a sample of TruVic's product to evaluate, it appears that at least claim one of Inari's U.S. Patent Nos. 11,559,382 and 11,744,691 may read on the Symphony system. The allowed claims of published application 17/976,711 (Publication No.

¹ We understand that TruVic Medical, Inc. is a subsidiary of Imperative Care, Inc. and may be changing its name to Imperative Care Vascular (or using the latter as d/b/a). We collectively refer to all three (TruVic Medical, Inc., Imperative Care, Inc., and Imperative Care Vascular, to the extent it exists as a separate entity) here as "TruVic."

Imperative Care, Inc.
TruVic Medical, Inc.
Page 2

20230062809) also appear to read on the system. Published applications 17/498,642 (Publication No. 20220240959) and 17/865,307 (Publication No. 20220346814) also appear relevant. While not clear from the literature alone, the system might also infringe patents directed to the design of the hemostasis valve in Inari's products, including U.S. Patents No. 11,554,005, 11,697,011, and/or 11,697,012 and published U.S. Patent Application 17/226,318 (Publication No. 20210290925). The allowed claims of 18/142,518 also appear to read on the system. For your convenience, Attachment B to this letter contains a copy of each of these ten patents and applications. Please understand, however, that the patents and published applications included in Attachment B were collected based on our current incomplete information, and that TruVic's Symphony and Prodigy products may infringe other Inari patents as well, including others listed in Attachment A.

Inari would like to avoid any dispute and litigation. At the same time, Inari has invested millions of dollars in developing the innovations covered by its patent rights and millions more in associated clinical trials, and cannot ignore the unauthorized use of those rights, particularly when infringement directly impacts Inari's sales, profits, and reputation as an innovator amongst doctors, patients, and the industry.

Given the above, please confirm that TruVic will cease or delay any launch of its Symphony Thrombectomy system until the patent issues above are resolved. To the extent that TruVic genuinely believes it is not infringing any of Inari's rights, please give us the factual and legal basis for your opinion. Further, to avoid any misunderstanding as to the Symphony system itself, we ask that you provide us a sample of the system so there is no dispute as to its structure or functionality.

Given the importance of these issues, please respond or have TruVic's counsel respond and provide us the sample of the Symphony product within two weeks. If TruVic's counsel would like to discuss this matter in the interim, they are welcome to contact me. Thank you for your attention to this matter.

Sincerely,



Ramsey M. Al-Salam

Enclosures

ATTACHMENT A

INARI MEDICAL PATENT GRANT/PUBLICATION LIST

US7,686,825	US2021/0022843A1	CNZL201680076244.5	CA3114285
US8,252,020	US2021/0113224A1	CNZL201780080361.3	CA3157521
US8,784,434	US2021/0186541A1	CNZL201880071533.5	CA3164925
US8,956,386	US2021/0236148A1	DE3364891	CA3185495
US8,968,330	US2021/0290925A1	DE60 2013 071 835.0	CA3190598
US9,259,237	US2021/0378694A1	DK2897536	CA3197631
US9,408,620	US2022/0000505A1	DK3364891	CA3198851
US9,526,864	US2022/0000506A1	EP2897536	EP4204058
US9,526,865	US2022/0000507A1	EP3364891	JP2018-537229
US9,700,332	US2022/0015798A1	ES2897536	JP2021-534851
US9,717,519	US2022/0022898A1	ES3364891	JP2022-173382
US9,844,387	US2022/0039815A1	FI2897536	JP2022-173563
US9,848,975	US2022/0125451A1	FI3364891	JP2022-551992
US10,004,531	US2022/0142638A1	FR2897536	JP2023-509330
US10,016,266	US2022/0151647A1	FR3364891	JP2023-537487
US10,045,790	US2022/0152355A1	GB2897536	JP2023534895
US10,098,651	US2022/0160382A1	GB3364891	CN106470728
US10,238,406	US2022/0160383A1	GR2897536	CN115151205
US10,335,186	US2022/0211400A1	GR3364891	CN115300748
US10,342,571	US2022/0240959A1	IE2897536	CN116234508
US10,349,960	US2022/0346813A1	IE3364891	CN116367876
US10,524,811	US2022/0346814A1	JP6438495	CN116421266
US10,588,655	US2022/0362512A1	JP7253376	CN116421876
US10,695,159	US2023/0046775A1	JP7254775	CN109069790A
US10,709,471	US2023/0062809A1	JP7324264	CN112867455A
US10,799,331	US2023/0070120A1	NL2897536	CN113796927A
US10,912,577	US2023/0200970A1	NL3364891	CN114845648A
US11,000,682	US2023/0218310A1	NO2897536	EP3094363
US11,058,445	US2023/0218313A1	NO3364891	EP3389757
US11,058,451	US2023/0233311A1	PT2897536T	EP3528717
US11,147,571	US2023/0240705A1	PT3364891	EP3678731
US11,154,314	US2023/0240706A1	SE2897536	EP3821830
US11,433,218	US2023/0241302A1	SE3364891	EP3836855
US11,529,158	US2023/0248380A1	AU2019321256	EP4044938
US11,554,005	US2023/0270991A1	AU2020368528	EP4076225
US11,559,382	AT2897536	AU2020407593	EP4161396
US11,642,209	AT3364891	AU2021245137	EP4192552
US11,648,028	AU2015274704	AU2021283979	EP4233744
US11,697,011	AU2016341439	AU2021320890	EP4243701
US11,697,012	AU2018328011	AU2021378284	EP3019097
US11,744,691	BE2897536	AU2021381331	JP2023-76579
US2015/0238207A1	BE3364891	AU2022235556	WO2022/109034
US2016/0113666A1	CA2939315	AU2023219946	WO2023/137341
US2016/0143721A1	CH2897536	CA3002154	WO2023/147353
US2018/0256178A1	CH3364891	CA3074564	WO2023/154612